Article Clinical Trials Data Microdosing 
The Cannigma
MARCH 7, 2021
This article was first published on Analytical Cannabis. People may not have to microdose psychedelics to feel their wellbeing benefits, according to a new study – they just have to believe they’ve microdosed them. Microdosing – regularly taking low doses of LSD or psilocybin – has gained popularity in recent years.
Cannabis Law Report
JUNE 19, 2022
For example, compounds such as psilocybin, mescaline, ibogaine, and LSD are being evaluated in clinical trials, but the compounds themselves are unpatentable because their existence is well documented in the prior art. Originally Published At Microdose. However, that does not mean that the path to patents is closed off.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JULY 9, 2022
Desperate to find any solution, she tried microdosing psilocybin mushrooms after researching the practice online. For Thornton, however, microdosing psilocybin mushrooms was a question of life or death. “I I decided to try microdosing psilocybin for depression because nothing else was working for me,” explains Thornton. “I
CannaMD
OCTOBER 7, 2019
In 2011, researchers published cross-sectional data from two population-based surveys including over 50,000 respondents. The biological behaviors and results described in this article are presently thought to be a specific consequence of THC consumption. Believe it or not, science says: YES. Take the American Journal of Epidemiology.
Cannabis Law Report
JUNE 4, 2021
Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. She is author, co-author, and co-editor of twenty-two books, two special-edition journals, and several peer-reviewed articles.
Expert insights. Personalized for you.
120 
Let's personalize your content